Guggenheim initiated coverage of GeneDx (WGS) with a Buy rating and $88 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx Holdings: Positioned for Growth in Whole Genome Sequencing with Strong NICU Market Potential
- GeneDx management to meet with BTIG
- GeneDx Holdings: Strong Buy Rating Backed by Projected Growth and Competitive Edge
- GeneDx upgraded to Buy from Hold at Jefferies
- GeneDx price target lowered to $110 from $135 at TD Cowen